An Evaluation of Navina Mini, a New Trans-anal Irrigation (TAI) Device in Children and Adolescents

Last updated: January 28, 2025
Sponsor: Wellspect HealthCare
Overall Status: Active - Recruiting

Phase

N/A

Condition

Constipation

Gastrointestinal Diseases And Disorders

Bowel Dysfunction

Treatment

Navina Mini

Clinical Study ID

NCT06385249
NAV-0012
  • Ages 3-17
  • All Genders

Study Summary

The study is designed to deliver further information on clinical benefit, patients' satisfaction, and perception of handling and to confirm safety of Navina Mini when used in children and adolescents.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Signed informed consent

  • Male and female children/adolescents between 3 and 17 years of age at the time ofinclusion

  • Diagnosis of at least one of the following:

  • functional constipation not well treated with oral laxatives

  • functional fecal incontinence, either retentive or non-retentive (FNRFI:Functional Non-Retentive Fecal Incontinence) not well treated with orallaxatives

  • neurogenic bowel dysfunction due to spinal abnormalities and/or spinal cordinjury or cerebral palsy

  • patient with sequelae of anorectal malformations to Hirschsprung disease

  • Fecal Incontinence (FI) due to iatrogenic injury including tumor surgerysequelae

  • Symptom duration of > 3 months

  • Subject and/or their legally designated representative can communicate in writtenand oral Swedish language

Exclusion

Exclusion Criteria:

  • Children/adolescents previously treated with, or currently in need of, high volumeTAI, i.e., volume > 250 ml

  • Confirmed pregnancy at the time of enrollment

  • Participating in another clinical investigation interfering with this investigation

  • Subjects with an active, symptomatic, inflammatory bowel disease, radiationproctitis, and or active perianal fistula disease

  • Rectal bleeding of uncertain origin or active hemorrhoidal bleeding

  • < 6 months after anal or colorectal surgery

  • Ongoing anti-coagulant therapy (i.e., NOACS, heparin, warfarin)

  • Ischemic colitis

  • Active anal fissure

  • Inability to use the product or anyone to assist in its usage (hand functionassessment)

  • Person not suitable for the investigation according to the investigator's judgment

Study Design

Total Participants: 27
Treatment Group(s): 1
Primary Treatment: Navina Mini
Phase:
Study Start date:
April 03, 2024
Estimated Completion Date:
May 31, 2025

Study Description

This is an uncontrolled, prospective, multicentre post-market clinical follow-up investigation that will enroll male and female children /adolescents with a need for low-volume transanal irrigation (TAI) as judged by the investigator or designee.

A total of 27 subjects in need of low-volume TAI will be recruited from 2-3 sites in Sweden and will be treated with Navina Mini as per product intended purpose and per instruction of use. Participating subjects will perform three visits during the clinical investigation and will be followed for a total of four (4) to six (6) weeks.

The study is designed to deliver further information on clinical benefit, patients' satisfaction, and perception of handling and to confirm device safety when used in children and adolescents.

Connect with a study center

  • H.K.H. Kronprinsessan Victorias Barn- och ungdomssjukhus Universitetssjukhuset

    Linköping,
    Sweden

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.